Over 1,000 Cardiac Patients Treated with Genesis Robotic System
April 13 2023 - 9:06AM
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical
robotics for minimally invasive endovascular intervention, today
announced that over 1,000 cardiac arrhythmia patients have been
treated using the Genesis Robotic Magnetic Navigation (RMN) system.
Genesis RMN, the latest innovation in
Stereotaxis’ robotic technology, was first used in late 2020
following regulatory clearances in the United States and Europe.
Since then, physicians at eight global hospitals have treated over
1,000 patients using Genesis RMN. These hospitals include Helsinki
University Central Hospital, Banner University Medical Center
Phoenix, Princess Grace Hospital Center in Monaco, Missouri Baptist
Medical Center, HonorHealth Scottsdale Shea Medical Center,
Poland’s National Institute of Cardiology, Corewell Health Meijer
Heart Center in Michigan, and Broward Health Medical Center in Fort
Lauderdale. Additional hospitals are in the process of installing
the technology with a total of nearly two dozen robotic systems
ordered.
The Genesis RMN system introduces the benefits
of robotic precision and safety to cardiac ablation, a common
minimally invasive procedure to treat arrhythmias. Tens of millions
of individuals worldwide suffer from arrhythmias – abnormal heart
rhythms that result when the heart beats too quickly, too slowly,
or with an irregular pattern. When left untreated, arrhythmias may
significantly increase the risk of stroke, heart failure, and
sudden cardiac arrest. Physicians have used Genesis RMN to treat a
broad spectrum of arrhythmia patients, including the underserved
community of patients with complex cardiac disease that cannot be
treated well or at all without Stereotaxis’ robotic technology.
“We are pleased to celebrate the pioneering
physicians and hospitals that demonstrated the clinical value of
Genesis RMN for patients, physicians, and health systems through
robust regular use,” said David Fischel, Chairman and CEO of
Stereotaxis.
About StereotaxisStereotaxis
(NYSE: STXS) is a pioneer and global leader in innovative surgical
robotics for minimally invasive endovascular intervention. Its
mission is the discovery, development, and delivery of robotic
systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
expand access to minimally invasive therapy, and enhance
productivity, connectivity, and intelligence in the operating room.
Stereotaxis technology has been used to treat over 100,000 patients
across the United States, Europe, Asia, and elsewhere. For more
information, please visit www.stereotaxis.com
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability or willingness of customers to
purchase its technology, competitive factors, changes in healthcare
policy, dependence upon third-party vendors, timing of regulatory
approvals, the impact of pandemics or other disasters, and other
risks discussed in the Company's periodic and other filings with
the Securities and Exchange Commission. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release. There can be no assurance that the Company will
recognize revenue related to its purchase orders and other
commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Stereotaxis Contacts: David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2023 to Apr 2024